Here is a schematic of how 3+3 DE studies are carried out.
The cohorts can be thought of as running simultaneously (although enrollment rates sometimes mean patients are treated in a consecutive manner if enrollment is slow). My understanding is there is no delaying treatment while another patient is going through the protocol, this would most liekly be unethical given patients in early phase cancer trials often have very few other treatment options.
Pillar 3 - AML, page-112
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.65 | $179.8K | 108.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1437 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 3313 | 1 |
View Market Depth
| Last trade - 15.58pm 03/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |